Fibrocystic disease of the breast in premenopausal women: Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment

Joseph Monsonego, Marie Dominique Destable, Georges De Saint Florent, Jacques Amouroux, Jean Claude Kouyoumdjian, France Haour, Jean Luc Breau, Lucien Israel, Ana Maria Comaru-Schally, Andrew V. Schally

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Sixty-six patients with fibrocystic mastopathy were enrolled in the trial after being selected according to clinical, radioultrasonographic, and histologic criteria. No characteristic hormonal profile was noted in most patients (52%). Estrogen receptors or progesterone receptors, or both, were found in 57% of patients. Hormone receptor levels were correlated with atypical proliferative mastopathy (87.5%). Mastopathy was associated with a uterine fibroma or a fibromatous uterus in 73% of cases. All patients received intramuscular injections of a sustained delivery system (microcapsules) of luteinizing hormone releasing hormone agonist [d-Trp6]-LHRH, Ipsen-Biotech, Paris) for 3 to 6 months. In case of partial response at 3 months, an antiestrogen (tamoxifen, 40 mg/day, for estrogen receptor-predominant lesions) or a progestin (cyproterone acetate, 50 mg/day, for progesterone receptor-predominant lesions) was added to the luteinizing hormone releasing hormone agonist. A complete response was observed in more than half of the patients (n = 35, 53%) treated by [d-Trp6]-LHRH alone (n = 29) or associated with tamoxifen (n = 4) or cyproterone acetate (n = 2). A significant partial response was observed in 30 other patients (45%). Additionally, half of them received inhibitory drugs. The best responses were seen with cyst reformation (complete response, 100%) and fibrous block. Clinical responses to treatment with [d-Trp6]-LHRH alone were independent of hormone receptor status, but synergistic effects occurred with concomitant use of the corresponding inhibitory drugs. We conclude that chronic mastopathy, particularly when associated with uterine fibroma, can be successfully treated by luteinizing hormone releasing hormone analogs in premenopausal women.

Original languageEnglish (US)
Pages (from-to)1181-1189
Number of pages9
JournalAmerican journal of obstetrics and gynecology
Volume164
Issue number5 PART 1
DOIs
StatePublished - May 1991
Externally publishedYes

Keywords

  • estradiol receptors
  • luteinizing hormone releasing hormone analog
  • Proliferative mastopathy

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Fibrocystic disease of the breast in premenopausal women: Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment'. Together they form a unique fingerprint.

  • Cite this

    Monsonego, J., Destable, M. D., De Saint Florent, G., Amouroux, J., Kouyoumdjian, J. C., Haour, F., Breau, J. L., Israel, L., Comaru-Schally, A. M., & Schally, A. V. (1991). Fibrocystic disease of the breast in premenopausal women: Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. American journal of obstetrics and gynecology, 164(5 PART 1), 1181-1189. https://doi.org/10.1016/0002-9378(91)90680-P